Profile data is unavailable for this security.
About the company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
- Revenue in SEK (TTM)0.00
- Net income in SEK-34.70m
- Incorporated2008
- Employees3.00
- LocationIsofol Medical AB (publ)Biotech Center, Arvid Wallgrens Backe 20GOETEBORG 413 46SwedenSWE
- Phone+46 317972280
- Fax+46 317411701
- Websitehttps://isofolmedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipum AB (publ) | 0.00 | -44.17m | 271.52m | 5.00 | -- | 5.49 | -- | -- | -3.77 | -3.77 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -124.17 | -127.85 | -147.77 | -184.50 | -- | -- | -- | -293,228.70 | -- | -423.66 | 0.0344 | -- | -- | -- | 2.38 | -- | -- | -- |
Dicot Pharma AB | 233.09k | -50.94m | 299.90m | 3.00 | -- | 10.74 | -- | 1,286.64 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
Arctic Bioscience AS | 30.36m | -46.74m | 306.42m | 20.00 | -- | 1.35 | -- | 10.09 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
Magle Chemoswed Holding AB | 177.92m | 7.70m | 396.55m | 78.00 | 49.68 | 2.38 | 18.65 | 2.23 | 0.7125 | 0.7125 | 16.47 | 14.84 | 0.628 | 0.5621 | 10.52 | 2,281,000.00 | 2.72 | 2.52 | 3.59 | 3.52 | 87.81 | 85.67 | 4.33 | 3.92 | 0.6117 | 3.42 | 0.3208 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
Infant Bacterial Therapeutics AB | 0.00 | -142.27m | 426.99m | 9.00 | -- | 1.87 | -- | -- | -10.57 | -10.57 | 0.00 | 17.57 | 0.00 | -- | -- | 0.00 | -46.35 | -16.11 | -54.97 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
Isofol Medical AB (publ) | 0.00 | -34.70m | 434.48m | 3.00 | -- | 4.26 | -- | -- | -0.2164 | -0.2164 | 0.00 | 0.6309 | 0.00 | -- | -- | 0.00 | -24.29 | -66.73 | -28.91 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
Enzymatica AB (publ) | 44.95m | -55.95m | 441.78m | 17.00 | -- | 4.86 | -- | 9.83 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | -- | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
Orexo AB | 615.40m | -96.70m | 485.95m | 112.00 | -- | 19.93 | -- | 0.7897 | -2.81 | -2.81 | 17.86 | 0.7025 | 0.7239 | 1.06 | 2.42 | 5,305,173.00 | -11.38 | -6.41 | -17.08 | -9.99 | 88.22 | 86.76 | -15.71 | -11.83 | 1.51 | -0.5276 | 0.9612 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
Navamedic ASA | 525.16m | 23.81m | 530.79m | 45.00 | 22.30 | 2.22 | 13.78 | 1.01 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
Moberg Pharma AB (publ) | 4.93m | -22.75m | 555.41m | 9.00 | -- | 0.5723 | -- | 112.68 | -0.9608 | -0.9608 | 0.1936 | 20.27 | 0.0065 | -- | 0.4949 | -- | -3.02 | -- | -3.12 | -- | 65.19 | -- | -461.64 | -- | 12.32 | -- | 0.0043 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
IRLAB Therapeutics AB | 41.59m | -119.45m | 611.11m | 32.00 | -- | 8.78 | -- | 14.70 | -2.30 | -2.30 | 0.8018 | 1.34 | 0.1871 | -- | 0.9707 | 1,599,423.00 | -53.74 | -27.12 | -92.28 | -30.42 | -177.74 | -72.18 | -287.25 | -155.57 | -- | -360.98 | 0.4421 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
Holder | Shares | % Held |
---|---|---|
SEB Investment Management ABas of 28 Jun 2024 | 1.02m | 0.63% |
Handelsbanken Fonder ABas of 31 Jul 2024 | 900.00k | 0.56% |
FCG Fonder ABas of 31 Dec 2023 | 432.97k | 0.27% |
Skandia Investment Management ABas of 31 May 2024 | 159.45k | 0.10% |
Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 0.00 | 0.00% |